doi:10.1016/j.tibs.2004.01.007
Ils ne constituent pas des preuves scientifiques
To learn more about this report, Within the global anti-obesity drug market segmented by drug class, GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists hold the highest share with an estimated 23.1% in 2026, driven largely by their dual role in appetite regulation and glucose metabolism
Who It's For (Based on Trial Inclusion Criteria) BMI 30 (obesity) OR BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea) Adults ages 1875 (some trials include narrower age ranges) People who have tried lifestyle interventions (diet and exercise) without sufficient weight loss Those with type 2 diabetes seeking both glucose control and weight loss People with obesity-related conditions that would improve with major weight reduction Who Should Avoid Retatrutide Based on trial exclusion criteria and the drug's mechanism, retatrutide is likely not appropriate for: Pregnancy or breastfeeding: Not studied in these populations
Your provider may recommend anti-nausea medication (ondansetron, metoclopramide) for breakthrough symptoms, or adjust your escalation schedule based on tolerability
During this initial week, you might find that you cannot finish a meal that you previously would have finished entirely, or you may notice that food noisethe constant, intrusive thoughts about what to eat nextbegins to quiet down